Historique
Article de Périodique
Ecstasy: pharmacodynamic and pharmacokinetic interactions (2004)
(Ecstasy : interactions pharmacodynamiques et pharmacocinétiques)
Auteur(s) :
OESTERHELD J. R. ;
ARMSTRONG, S. C. ;
COZZA K. L.
Année
2004
Page(s) :
84-87
Langue(s) :
Anglais
Refs biblio. :
24
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus mots-clés
MDMA-ECSTASY
;
PHARMACOLOGIE
;
PHARMACOCINETIQUE
;
RAVE
;
POLYCONSOMMATION
;
TOXICITE
Résumé :
At "raves," young people dance and ingest illicit drugs, the most common of which is MDMA (N-methyl-3,4,-methylenedioxymethamphetamine) or "ecstasy." This drug is metabolized principally through the cytochrome P450 (CYP450) 2D6 enzyme. Pharmacokinetic drug-drug interactions can occur if MDMA is combined with other recreational or therapeutic drugs that are 2D6 inhibitors. Ecstasy concentration may increase to cause toxicity. Since ecstasy is pro-serotonergic, it may also be involved in pharmacodynamic drug-drug interactions when other pro-serotonergic drugs are combined with it, leading to a central serotonin syndrome. Some drugs are both pro-serotonergic and CYP450 2D6 inhibitors and, if co-administered with ecstasy, may cause both pharmacokinetic and pharmacodynamic drug-drug interactions.
Affiliation :
Spurwink School, Portland, Me, USA
Cote :
A01694